Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes
worldwide. The number affected is increasing rapidly with alarming trends in children and …

Abstract Glucagon-like peptide-1 (GLP-1) controls islet hormone secretion, gut motility, and
body weight, supporting development of GLP-1 receptor agonists (GLP-1RA) for the …

Background Combining the GLP-1 receptor agonist semaglutide with the long-acting amylin
analogue cagrilintide has weight-loss benefits; the impact on glycated haemoglobin (HbA …

Nearly half of Americans are projected to have obesity by 2030, underscoring the pressing
need for effective treatments. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) …

The World Health Organization (WHO) refers to obesity as abnormal or excessive fat
accumulation that presents a health risk. Obesity was first designated as a disease in 2012 …

Obesity is a chronic disease associated with increased risk of obesity-related complications
and mortality. Our better understanding of the weight regulation mechanisms and the role of …

Long-acting analogues of the naturally occurring incretin, glucagon-like peptide-1 (GLP-1)
and those modified to interact also with receptors for glucose-dependent insulinotropic …

Peptides and proteins are widely used to treat a range of medical conditions; however, they
often have to be injected and their effects are short-lived. These shortcomings of the native …

Abstract Losses of 5–10% or more of initial body weight are associated with improvements
in obesity-related comorbidities. However, attaining and sustaining this level of weight loss …

Chronic kidney disease (CKD) causes considerable morbidity, mortality, and health
expenditures worldwide. Obesity is a significant risk factor for CKD development, partially …